Announcements Trials
Browse Landscape

Phase

Phase 1 2

Status

Recruiting 3Completed 2Unknown 1Terminated 1

Sponsor Class

OTHER 1NIH 1

Study Type

Interventional 2

Sponsor

Cancer Type

Lymphoid 2Other hematologic neoplasm 1Dermatologic 1

Conditions

Leukemia, Myeloid, Acute 78Leukemia, Lymphocytic, Chronic, B-Cell 77Leukemia 77Myelodysplastic Syndromes 61Lymphoma 51Precursor Cell Lymphoblastic Leukemia-Lymphoma 47Multiple Myeloma 46Lymphoma, Non-Hodgkin 45Hodgkin Disease 36Leukemia, Myelogenous, Chronic, BCR-ABL Positive 31Hematologic Neoplasms 27Melanoma 26Recurrence 20Lymphoma, Follicular 18Lymphoma, Mantle-Cell 17Myeloproliferative Disorders 16Graft vs Host Disease 15Primary Myelofibrosis 14Lymphoma, Large B-Cell, Diffuse 14Lymphoma, B-Cell 13Neoplasms, Plasma Cell 12Lymphoma, B-Cell, Marginal Zone 11Leukemia, Myelomonocytic, Chronic 10Anemia, Aplastic 10Neoplasms 9Hematologic Diseases 9Neoplasm Metastasis 8Blast Crisis 8Anemia, Refractory, with Excess of Blasts 8Ovarian Neoplasms 7

Interventions

Cyclophosphamide 19romidepsin 15fludarabine phosphate 13Whole-Body Irradiation 13Peripheral Blood Stem Cell Transplantation 11Mycophenolic Acid 11Doxorubicin 11Vincristine 10Prednisone 10Cyclosporine 1010-propargyl-10-deazaaminopterin 10Gemcitabine 8Etoposide 8Alemtuzumab 8Bortezomib 6Dexamethasone 5Busulfan 5Brentuximab Vedotin 5mogamulizumab 4denileukin diftitox 4darinaparsin 4Vitamin B 12 4Nivolumab 4Lenalidomide 4Folic Acid 4Carboplatin 4carfilzomib 3belinostat 3Tacrolimus 3Rituximab 3

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Completed × Lymphoma, T-Cell, Peripheral × fludarabine × Clear all
NCT02512497 2025-09-19

Romidepsin Maintenance After Allogeneic Stem Cell Transplantation

Ohio State University Comprehensive Cancer Center

Phase 1 Completed
23 enrolled
DermatologicLymphoidOther hematologic neoplasm

Lymphoma, Leukemia, Prolymphocytic, T-Cell, Lymphoma, T-Cell, Cutaneous, Lymphoma, T-Cell, Peripheral, Precursor T-Cell Lymphoblastic Leukemia-Lymphoma

NCT03049449 2023-01-18

T Cells Expressing a Fully-Human Anti-CD30 Chimeric Antigen Receptor for Treating CD30-Expressing Lymphomas

National Institutes of Health Clinical Center (CC)

Phase 1 Completed
26 enrolled 19 charts
Lymphoid

Immunoblastic Lymphadenopathy, Lymphoma, Large B-Cell, Diffuse, Lymphoma, T-Cell, Peripheral, Lymphoma, Large-Cell, Anaplastic, Lymphoma, Extranodal NK-T-Cell, Enteropathy-Associated T-Cell Lymphoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡